title: Influence of methimazole and radioactive iodine treatment in the serum levels of the chemokine CXCL10 in hyperthyroid patients with Graves' disease.
abstract: The chemokine CXCL10 plays an important role in Graves' disease (GD); however, data regarding the effectiveness of therapy are contradictory. Serum CXCL10 levels in 31 hyperthyroid patients were measured before and after establishing euthyroidism: 16 newly diagnosed GD patients received methimazole (MMI), 15 relapsed GD patients were treated with radioactive iodine (RAI), and 18 healthy subjects served as a control group. Baseline serum CXCL10 levels were higher than in controls (MMI group 144.0 ± 48.24, RAI group 156.3 ± 71.81 and control 71.32 ± 26.03 pg/ml; p < 0.01). In the MMI group, serum CXCL10 levels decreased following euthyroidism at 6 months (76.51 ± 22.06 pg/ml; p < 0.01) and 12 (76.42 ± 34.07 pg/ml; p < 0.01). In the RAI group, serum CXCL10 levels decreased after 3, 6, 9, and 12 months of RAI administration (82.37 ± 55.01, 66.35 ± 48.62, 68.76 ± 28.87, and 74.94 ± 49.74 pg/ml, respectively; p < 0.05). Elevated serum TRAb levels in the MMI group (33.15 ± 30.84) decreased at 6 months (14.64 ± 16.57 IU/l; p = 0.0070), whereas in the RAI group (44.61 ± 60.66 IU/l) they increased to a peak level at 6 months (66.40 ± 104.2 IU/l; p = 0.003), which was significantly higher than those of the MMI group, but were decreased at 12 months (28.91 ± 35.13 IU/l). Serum CXCL10 levels correlated with FT3 (r = 0.48, p < 0.0001), FT4 (r = 0.47, p < 0.0001) and TRAb (r = 0.37, p = 0.0014). In conclusion, these data show a relationship between serum CXCL10 and GD activity and suggest that a more complex mechanism is involved in the generation of the thyroid auto-antibodies TPOAb and TRAb.
authors.affiliation: Endocrinology Division, Hospital do Servidor Publico Estadual de São Paulo-IAMSPE, São Paulo, SP, Brazil.
authors.forename: A C
authors.initials: AC
authors.lastname: Leite
authors.forename: A B P
authors.initials: AB
authors.lastname: Pedro
authors.forename: J H
authors.initials: JH
authors.lastname: Romaldini
mesh_terms: D000328:Adult; D013956:Antithyroid Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D054357:Chemokine CXCL10 / Q000097:blood*; D005260:Female; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008297:Male; D008713:Methimazole / Q000627:therapeutic use*; D008875:Middle Aged
chemical_list: D013956:Antithyroid Agents; D054357:Chemokine CXCL10; D007457:Iodine Radioisotopes; D008713:Methimazole